Given their dual role in cancer, TLRs present both opportunities and challenges as therapeutic targets. TLR agonists and antagonists are being developed to modulate TLR activity. For example, TLR7 and TLR9 agonists are being tested as adjuvants in cancer vaccines to boost anti-tumor immunity. Conversely, TLR4 antagonists are being explored to reduce inflammation-driven tumor progression.
